Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy

BCMA/CD3-targeting bispecific antibodies (BsAb) are a recently developed immunotherapy class that shows potent tumor killing activity in multiple myeloma. Here, we investigated a murine BCMA/CD3-targeting BsAb in the immunocompetent Vk*MYC model and its immunomodulatory imide drug (IMiD)–sensitive d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer Discov
Main Authors: Meermeier, Erin W., Welsh, Seth J., Sharik, Meaghen E., Du, Megan T., Garbitt, Victoria M., Riggs, Daniel L., Shi, Chang-Xin, Stein, Caleb K., Bergsagel, Marco, Chau, Bryant, Wheeler, Matthew L., Bezman, Natalie, Wang, Feng, Strop, Pavel, Bergsagel, P. Leif, Chesi, Marta
Formato: Artigo
Idioma:Inglês
Publicado em: American Association for Cancer Research 2021
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8266040/
https://ncbi.nlm.nih.gov/pubmed/34258584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2643-3230.BCD-21-0038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados